CIC
KYMR icon

Cornercap Investment Counsel’s Kymera Therapeutics KYMR Stock Holding History

Cornercap Investment Counsel’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10,806
Closed -$275K – 643
2023
Q4 		$275K Buy
10,806
+53
+0.5% +$948 0.05% 492
2023
Q3 		$149K Buy
+10,753
New +$216K 0.03% 513

Other funds holding KYMR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Cornercap Investment Counsel's KYMR Position: Q1 2024 in Review

Cornercap Investment Counsel sold out of Kymera Therapeutics (KYMR) in Q1 2024, closing a stake of 10,806 shares — an estimated $275K sold.

Cornercap Investment Counsel first reported a position in KYMR in Q3 2023 and held it in 2 quarters. The position peaked at $275K in Q4 2023. 164 funds tracked by Wall St. Rank hold KYMR as of Q1 2024.

  • Cornercap Investment Counsel reported no remaining Kymera Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Cornercap Investment Counsel sold 10,806 Kymera Therapeutics shares in Q1 2024, an estimated $275K.
  • Cornercap Investment Counsel first reported a position in Kymera Therapeutics in Q3 2023 and held it in 2 quarters.
  • Cornercap Investment Counsel's Kymera Therapeutics position peaked at $275K in Q4 2023.
  • 164 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2024.

Based on Cornercap Investment Counsel's 13F filing for Q1 2024, filed 10 May 2024.